GlassScriptPhysician profile
Danesh Mazloomdoost
NPI 1851447072
$1,938.92
in general payments reported to CMS, 2019-2025
25 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $130 · 2021: $281 · 2022: $197 · 2023: $229 · 2024: $82.33 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $260.46 | 2019-2024 | Senza |
| Globus Medical, INC. | $257.01 | 2025 | Senza |
| Abbott Laboratories | $223.23 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $129.87 | 2023 | Quviviq |
| Amgen INC. | $126.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $115.68 | 2019-2021 | |
| Vertos Medical, INC. | $95.41 | 2019 | |
| Abbvie INC. | $92.76 | 2021-2025 | |
| Boston Scientific Corporation | $78.42 | 2019-2025 | General - Pain Management |
| Medtronic USA, INC. | $69.45 | 2019 | |
| Neuronetics, INC. | $59.04 | 2019-2022 | |
| Tersera Therapeutics LLC | $56.72 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $56.08 | 2020-2021 | |
| Si-Bone, INC. | $44.05 | 2020-2022 | |
| Fidia Pharma USA INC. | $41.85 | 2019-2025 | Hymovis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $31.95 | 2021 | |
| Pfizer INC. | $31.80 | 2025 | |
| Axsome Therapeutics, INC. | $28.55 | 2024 | Auvelity |
| Avanos Medical | $27.76 | 2024 | Generator |
| Orthogenrx INC. | $24.69 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.32 | 2023 | Rexulti |
| Tonix Medicines, INC. | $18.18 | 2025 | Tonmya |
| Sanofi-Aventis U.S. LLC | $17.83 | 2021 | |
| Ibsa Pharma INC. | $15.75 | 2020 | |
| Upsher-Smith Laboratories LLC | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danesh Mazloomdoost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.